Turning Point Brands, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone quarterly filing; unaudited fourth-quarter results are also disclosed. TPB manufactures, markets and distributes tobacco products, smoking accessories and other nicotine-related products through Zig-Zag Products, Stoker’s Products and Creative Distribution Solutions (CDS).
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $405.4 million | $415.0 million |
| Gross profit / margin | $203.2 million / 50.1% | $205.5 million / 49.5% |
| Operating income | $82.6 million | $75.5 million |
| Net income attributable to TPB | $38.5 million | $11.6 million |
| Diluted EPS | $2.01 | $0.64 |
| Adjusted EBITDA | $95.3 million | $97.6 million |
| Cash from operations | $66.9 million | $30.3 million |
Capital expenditures were $5.7 million. Cash and cash equivalents were $117.9 million at year-end. The company reported $368.5 million of debt principal: $250.0 million of 5.625% senior secured notes due 2026 and $118.5 million of 2.50% convertible notes due July 2024. The new asset-backed revolver has $75.0 million of commitments, approximately $60.0 million available at year-end and $1.4 million of letters of credit outstanding; no borrowings were drawn. Company-defined working capital (current assets less cash and current liabilities) was $49.4 million, down from $109.9 million.
Material changes versus the prior period
- Sales fell 2.3%, mainly reflecting lower CDS volumes and lower Zig-Zag sales, partly offset by Stoker’s growth.
- Stoker’s sales rose 10.5%; volume increased 4.2% and price/mix 6.3%, with growth led by moist snuff tobacco.
- Zig-Zag sales declined 5.2%, reflecting anticipated U.S. rolling-paper and wrap declines, reduced trade inventory and a discontinued Canadian product line; CLIPPER growth partly offset these factors.
- CDS sales declined 14.3% and gross margin fell to 25.3% from 29.5%, primarily due to lower volume and channel mix. TPB restructured CDS in 2023 to exit certain unprofitable brands and narrow its focus.
- Operating income increased 9.4%, while net income attributable to TPB rose substantially from 2022, which included a $27.6 million goodwill and intangible impairment charge. The 2023 result also included investment losses, a higher effective tax rate and unusual items.
- Operating cash flow more than doubled, primarily due to the timing of inventory and other working-capital movements; inventory fell to $99.0 million from $119.9 million.
Fourth quarter: Net sales were $97.1 million versus $103.4 million in Q4 2022; gross profit was $50.5 million versus $49.6 million. Net income attributable to TPB was $10.1 million versus a $16.3 million loss, with the prior-year quarter affected by impairment charges.
Outlook, commentary and notable items
- No quantified revenue, earnings or cash-flow guidance is provided in the filing. Management describes growth plans around distribution gains, product innovation, international expansion, and selective acquisitions. It planned a broader FRĒ nicotine-pouch rollout in 2024.
- TPB recorded a $15.2 million inventory reserve following tornado damage at a third-party tobacco warehouse and a corresponding $15.2 million insurance recovery receivable; management expects full recovery and no delivery disruption. A separate $4.3 million federal excise tax refund and a $4.0 million legal-settlement gain also benefited reported results.
- FDA premarket authorization and enforcement remain significant uncertainties for nicotine and other regulated products. TPB says it has spent approximately $26 million on PMTA filings and supplements; authorization of products is not assured.
- Supply-chain concentration is material: Swedish Match manufactures all of TPB’s loose-leaf chewing tobacco, and RTI supplies Zig-Zag cigarette papers and related products under long-term agreements. The filing notes risks from supplier disruption, licensing terms, regulation, taxes, competition, illicit products and economic pressure.
- The auditor gave an unqualified opinion on the financial statements but concluded that internal control over financial reporting was ineffective at year-end due to a material weakness in IT general controls over user access and program change management. No financial-statement misstatement was identified. Management’s remediation plan includes a new ERP system in 2024 and improved documentation, testing and oversight.
- TPB repurchased $44.0 million principal of convertible notes during 2023. Management expects cash, free cash flow and ABL availability to support the July 2024 maturity; the filing does not establish that refinancing or repayment is completed.
Important facts for investors to verify
- Progress and cost of remediating the IT-control material weakness, including ERP implementation and subsequent auditor assessment.
- Repayment or refinancing of the $118.5 million convertible notes due July 2024, and actual borrowing availability under the borrowing-base revolver.
- Receipt of the $15.2 million insurance recovery and whether tobacco supply or deliveries are affected by the warehouse loss.
- FDA decisions, enforcement changes or new state rules affecting PMTA-covered products, FRĒ pouches and CDS sales.
- Whether Stoker’s growth can offset continued weakness in Zig-Zag and CDS, including CDS margins after the restructuring.
- Performance and impairment risk of equity and debt investments; 2023 investment losses were $11.9 million, including impairment charges.